Cargando…

Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review

Clocortolone pivalate 0.1% cream is a class IV mid-strength topical glucocorticoid. After topical application the glucocorticoid achieves higher concentration in inflamed skin compared with normal skin. Furthermore, pharmacologic studies have shown that there is little systemic absorption of clocort...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Sanjay, Mann, Baldeep Kaur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393117/
https://www.ncbi.nlm.nih.gov/pubmed/22791998
http://dx.doi.org/10.2147/CCID.S23227
_version_ 1782237677645463552
author Singh, Sanjay
Mann, Baldeep Kaur
author_facet Singh, Sanjay
Mann, Baldeep Kaur
author_sort Singh, Sanjay
collection PubMed
description Clocortolone pivalate 0.1% cream is a class IV mid-strength topical glucocorticoid. After topical application the glucocorticoid achieves higher concentration in inflamed skin compared with normal skin. Furthermore, pharmacologic studies have shown that there is little systemic absorption of clocortolone pivalate and hence no adrenal suppression. Systematic review was performed to evaluate the efficacy and safety of the glucocorticoid. PubMed, the Cochrane Library, and individual websites of the top 20 dermatology journals were searched using a defined strategy. Following the selection criteria, eight clinical trials were selected, of which five were randomized controlled trials. The trials mainly included patients with atopic dermatitis and eczemas. Quality appraisal of randomized controlled trials was done using the Delphi list, which showed that the trials had weaknesses in several items. The results of the systematic review tend to show that clocortolone pivalate cream is generally effective with early onset of action and has a good safety profile in the treatment of these conditions. Further studies comparing this glucocorticoid with other glucocorticoids and treatments in steroid-responsive dermatoses are desirable.
format Online
Article
Text
id pubmed-3393117
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33931172012-07-12 Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review Singh, Sanjay Mann, Baldeep Kaur Clin Cosmet Investig Dermatol Review Clocortolone pivalate 0.1% cream is a class IV mid-strength topical glucocorticoid. After topical application the glucocorticoid achieves higher concentration in inflamed skin compared with normal skin. Furthermore, pharmacologic studies have shown that there is little systemic absorption of clocortolone pivalate and hence no adrenal suppression. Systematic review was performed to evaluate the efficacy and safety of the glucocorticoid. PubMed, the Cochrane Library, and individual websites of the top 20 dermatology journals were searched using a defined strategy. Following the selection criteria, eight clinical trials were selected, of which five were randomized controlled trials. The trials mainly included patients with atopic dermatitis and eczemas. Quality appraisal of randomized controlled trials was done using the Delphi list, which showed that the trials had weaknesses in several items. The results of the systematic review tend to show that clocortolone pivalate cream is generally effective with early onset of action and has a good safety profile in the treatment of these conditions. Further studies comparing this glucocorticoid with other glucocorticoids and treatments in steroid-responsive dermatoses are desirable. Dove Medical Press 2012-06-22 /pmc/articles/PMC3393117/ /pubmed/22791998 http://dx.doi.org/10.2147/CCID.S23227 Text en © 2012 Singh and Mann, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Singh, Sanjay
Mann, Baldeep Kaur
Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review
title Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review
title_full Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review
title_fullStr Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review
title_full_unstemmed Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review
title_short Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review
title_sort clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393117/
https://www.ncbi.nlm.nih.gov/pubmed/22791998
http://dx.doi.org/10.2147/CCID.S23227
work_keys_str_mv AT singhsanjay clinicalutilityofclocortolonepivalateforthetreatmentofcorticosteroidresponsiveskindisordersasystematicreview
AT mannbaldeepkaur clinicalutilityofclocortolonepivalateforthetreatmentofcorticosteroidresponsiveskindisordersasystematicreview